ScholarIQanswers from OpenAlex & ORCID
Jennifer L. Harris
ResearcherPublications, citations & collaboration network
Jennifer L. Harris is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jennifer L. Harris have?
ScholarIQindexed works
Jennifer L. Harris has 300 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jennifer L. Harris have?
ScholarIQcitation count
Jennifer L. Harris has 28,148 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jennifer L. Harris?
ScholarIQh-index
Jennifer L. Harris has an h-index of 69 in OpenAlex.
What is the i10-index of Jennifer L. Harris?
ScholarIQi10-index
Jennifer L. Harris has an i10-index of 182 in OpenAlex.
What is the ORCID of Jennifer L. Harris?
ScholarIQorcid
The ORCID for Jennifer L. Harris is on the source record.
What is the OpenAlex record for Jennifer L. Harris?
ScholarIQopenalex
The OpenAlex for Jennifer L. Harris is on the source record.
What are the most-cited papers on Jennifer L. Harris?
ScholarIQmost cited works
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, K. Venkatesan, Adam A. Margolin, Sung Joon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané‐Valbuena, Felipa Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying Karen Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor, Adam Crystal, Pierre‐Yves Michellys, Mark M. Awad, Noriko Yanagitani, Sung Joon Kim, AnneMarie Culazzo Pferdekamper, Jie Li, Shailaja Kasibhatla, Frank F. Sun, Xiuying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L. Harris, Alice T. Shaw, Jeffrey A. Engelman
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees, Afshin Dowlati, Kimberly Blackwell, Bert H. O’Neil, P. Kelly Marcom, Matthew J. Ellis, Beth Overmoyer, Suzanne F. Jones, Jennifer L. Harris, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Steve Mangum, Neil L. Spector
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sung Joon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank F. Sun, Auzon Steffy, AnneMarie Culazzo Pferdekamper, Allen G. Li, Sean B. Joseph, Young Ho Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo W. Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin C. Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, J. Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre‐Yves Michellys